Literature DB >> 21785953

Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.

Takao Nagashima, Akihito Maruyama, Yasuyuki Kamata, Seiji Minota.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21785953     DOI： 10.1007/s00296-011-2060-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  9 in total

1.  Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B.

Authors:  T Nagashima; S Minota
Journal:  Rheumatology (Oxford)       Date:  2008-10-14       Impact factor: 7.580

2.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

3.  Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.

Authors:  Dai Kishida; Yasuaki Okuda; Makoto Onishi; Masashi Takebayashi; Kenichiro Matoba; Kazuo Jouyama; Akihiro Yamada; Naoya Sawada; Sho Mokuda; Kiyoshi Takasugi
Journal:  Mod Rheumatol       Date:  2010-10-08       Impact factor: 3.023

4.  Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.

Authors:  Daisuke Ennishi; Yoshinobu Maeda; Nozomi Niitsu; Minoru Kojima; Koji Izutsu; Jun Takizawa; Shigeru Kusumoto; Masataka Okamoto; Masahiro Yokoyama; Yasushi Takamatsu; Kazutaka Sunami; Akira Miyata; Kayoko Murayama; Akira Sakai; Morio Matsumoto; Katsuji Shinagawa; Akinobu Takaki; Keitaro Matsuo; Tomohiro Kinoshita; Mitsune Tanimoto
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

5.  Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

Authors:  Clodoveo Ferri; Gianfranco Ferraccioli; Daniela Ferrari; Mauro Galeazzi; Giovanni Lapadula; Carlomaurizio Montecucco; Giovanni Triolo; Gabriele Valentini; Guido Valesini
Journal:  J Rheumatol       Date:  2008-08-01       Impact factor: 4.666

6.  High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Jun Yu; Alfred Sze-Lok Cheng; Grace Lai-Hung Wong; Hoi-Yun Chan; Eagle Siu-Hong Chu; Enders Kai-On Ng; Francis Ka-Leung Chan; Joseph Jao-Yao Sung; Henry Lik-Yuen Chan
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.

Authors:  Hayato Nakagawa; Shin Maeda; Haruhiko Yoshida; Ryosuke Tateishi; Ryota Masuzaki; Takamasa Ohki; Yoku Hayakawa; Hiroto Kinoshita; Minoru Yamakado; Naoya Kato; Shuichiro Shiina; Masao Omata
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

Review 9.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Trends Mol Med       Date:  2008-02-07       Impact factor: 11.951
  9 in total
  5 in total

Review 1.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

3.  Case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis C.

Authors:  Filippo Iebba; Fiorella Di Sora; Agapito Tarasi; Wilma Leti; Tatiana Montella; Francesco Montella
Journal:  Case Rep Med       Date:  2012-02-16

Review 4.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

5.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.